Overview of Best of Big Technology: How Ozempic Changes Our Bodies, Minds, and Economy — With Johann Hari
In this replay of a 2024 Big Technology Podcast interview, Alex Kantrowitz speaks with journalist and author Johann Hari about the rise of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, and how they are reshaping appetite, health, and the economy. Hari argues that these drugs are not just weight-loss tools, but a response to a deeper problem: the modern processed-food environment that drives overeating and obesity. The conversation covers the science of appetite, the promise and risks of GLP-1s, and the broader social consequences if these drugs become widely adopted.
Key themes
The “Cheesecake Rat” problem
Hari uses the “Cheesecake Park” experiment to illustrate how processed and ultra-processed foods can override natural satiety:
- Rats fed whole foods ate normally and stopped when full.
- When given bacon, candy bars, and cheesecake, they overate and became obese.
- After the junk food was removed, they often refused the healthy food, as if they no longer recognized it as food.
His larger point: modern food products are engineered to make people eat more, not necessarily because of a conspiracy, but because food companies are incentivized to maximize consumption.
Obesity as an environmental and industrial problem
Hari argues obesity is less about individual willpower and more about a food system dominated by:
- ultra-processed foods
- low-protein, highly palatable products
- marketing to children
- weak regulation
He frames the obesity crisis as the result of an “artificial problem” created by the modern food environment.
How Ozempic and GLP-1 drugs work
Satiety hormones and appetite control
Hari explains that the body naturally releases GLP-1 after eating, which signals fullness. GLP-1 drugs mimic this hormone and keep it active much longer:
- natural GLP-1 lasts only minutes
- injectable GLP-1 drugs can last about a week
- this dramatically increases satiety and reduces overeating
He describes his own experience as feeling full quickly, sometimes after just a few bites, and says he lost about 42 pounds in the first year.
More than just one drug
The discussion also touches on the broader class of GLP-1-style medications:
- Ozempic/Wegovy: act on GLP-1
- Mounjaro: acts on GLP-1 plus GIP
- future “triple agonist” drugs may act on three gut hormones
Hari notes that more than 200 related drugs are in development, and the field may keep expanding.
Benefits and risks
Major health benefits
Hari emphasizes that these drugs may substantially reduce disease risk, including:
- heart disease
- heart attack
- stroke
- diabetes complications
- some obesity-related cancers and other chronic illnesses
He compares the potential impact to one of the biggest public-health breakthroughs in decades.
Emotional and psychological risks
A major part of the conversation focuses on possible downsides:
- some people report reduced pleasure in food
- the drugs may dampen reward systems more broadly
- there are concerns about depression or suicidal thoughts in a minority of users
- some people may lose their coping mechanism for stress or grief, revealing unresolved emotional issues
Hari says that in his own case, food had long been a way to numb emotions, and Ozempic disrupted that pattern.
Weight regain and long-term uncertainty
Hari says the drugs often work only while they are being taken:
- stopping them commonly leads to weight regain
- long-term effects are still unknown
- there is concern that metabolism could worsen after stopping, especially if weight is regained
He stresses that the science is still evolving, especially around brain effects and long-term use.
Economic and societal implications
A potential shock to consumption
The conversation broadens from health to macroeconomics. Hari and Kantrowitz discuss how widespread GLP-1 use could change:
- food sales
- snack and dessert companies
- retail
- airlines, due to lower passenger weight
- consumer spending patterns more generally
The point is not that this is coordinated, but that two huge forces in capitalism may collide:
- the food industry, which profits from maximizing consumption
- pharma, which profits from reducing it
Early signs of market disruption
Examples mentioned include:
- concerns from brands like Nestlé and Krispy Kreme
- analysts downgrading sugary/snack-food stocks
- reports that airlines may spend less on fuel if average body weight falls
Hari suggests the economic ripple effects could be as transformative as the smartphone.
Children, prevention, and policy
The hardest question: should kids take GLP-1 drugs?
Hari says the children’s question is the most difficult issue in the debate:
- obesity in childhood creates severe long-term health risks
- but the long-term safety of these drugs in children is still unknown
- giving a child a medication they may have to take for decades is a major uncertainty
He does not dismiss parents who choose it, but argues the deeper problem is that society should not force children into a choice between obesity and risky medication.
Prevention should come first
Hari points to Japan as an example of reducing childhood obesity through policy and food culture rather than medication. His broader argument:
- regulate processed food more aggressively
- improve public health policy
- reduce the need for drugs in the first place
Bottom line
- GLP-1 drugs are a genuine scientific breakthrough, not a fad.
- They may help solve a major health crisis tied to obesity and chronic disease.
- But they also come with unresolved risks: emotional blunting, weight regain, long-term unknowns, and potential misuse.
- Their widespread adoption could reshape not just medicine, but the food industry, consumer behavior, and the wider economy.
- Hari’s core message: these drugs are powerful, but they are treating a problem created by a broken food system.